InMed Pharmaceuticals (NASDAQ:INM) Major Shareholder Buys $27,939.72 in Stock

Posted by George Bondi on Jun 10th, 2026

InMed Pharmaceuticals Inc. (NASDAQ:INM – Get Free Report) major shareholder Vivo Opportunity, Llc purchased 17,796 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were acquired at an average price of $1.57 per share, with a total value of $27,939.72. Following the purchase, the insider owned 590,175 shares in the company, valued at $926,574.75. This trade represents a 3.11% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Vivo Opportunity, Llc also recently made the following trade(s):

On Monday, June 8th, Vivo Opportunity, Llc purchased 32,500 shares of InMed Pharmaceuticals stock. The shares were acquired at an average price of $1.52 per share, with a total value of $49,400.00.
On Friday, June 5th, Vivo Opportunity, Llc purchased 55,011 shares of InMed Pharmaceuticals stock. The shares were acquired at an average price of $1.57 per share, with a total value of $86,367.27.
On Thursday, June 4th, Vivo Opportunity, Llc acquired 6,743 shares of InMed Pharmaceuticals stock. The shares were purchased at an average price of $1.57 per share, with a total value of $10,586.51.
On Wednesday, June 3rd, Vivo Opportunity, Llc acquired 7,783 shares of InMed Pharmaceuticals stock. The shares were purchased at an average price of $1.55 per share, with a total value of $12,063.65.
On Tuesday, June 2nd, Vivo Opportunity, Llc acquired 22,848 shares of InMed Pharmaceuticals stock. The shares were purchased at an average price of $1.52 per share, with a total value of $34,728.96.
On Monday, June 1st, Vivo Opportunity, Llc acquired 16,336 shares of InMed Pharmaceuticals stock. The shares were purchased at an average price of $1.55 per share, with a total value of $25,320.80.
On Thursday, May 21st, Vivo Opportunity, Llc acquired 34,000 shares of InMed Pharmaceuticals stock. The shares were purchased at an average price of $1.69 per share, with a total value of $57,460.00.
On Wednesday, May 20th, Vivo Opportunity, Llc acquired 56,210 shares of InMed Pharmaceuticals stock. The shares were purchased at an average price of $1.56 per share, with a total value of $87,687.60.

InMed Pharmaceuticals Stock Performance

InMed Pharmaceuticals stock traded down $0.02 during trading hours on Wednesday, reaching $1.51. 41,953 shares of the stock were exchanged, compared to its average volume of 5,061,547. The firm’s 50 day moving average is $1.01 and its 200 day moving average is $1.04. The stock has a market cap of $5.00 million, a P/E ratio of -0.52 and a beta of 0.98. InMed Pharmaceuticals Inc. has a 52-week low of $0.58 and a 52-week high of $5.50.

InMed Pharmaceuticals (NASDAQ:INM – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($94.44) by $93.75. InMed Pharmaceuticals had a negative net margin of 132.87% and a negative return on equity of 80.85%.

Institutional Investors Weigh In On InMed Pharmaceuticals

An institutional investor recently bought a new position in InMed Pharmaceuticals stock. Virtu Financial LLC purchased a new stake in InMed Pharmaceuticals Inc. (NASDAQ:INM – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 20,369 shares of the company’s stock, valued at approximately $45,000. Virtu Financial LLC owned 0.73% of InMed Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 20.12% of the company’s stock.

InMed Pharmaceuticals News Summary

Here are the key news stories impacting InMed Pharmaceuticals this week:

Positive Sentiment: Major shareholder Vivo Opportunity, LLC has been steadily increasing its position through multiple purchases in late May and early June, including a 32,500-share buy at $1.52 and several other buys around $1.55 to $1.69 per share. Repeated insider accumulation can be viewed as a vote of confidence in InMed Pharmaceuticals’ prospects.
Neutral Sentiment: The latest filings show Vivo Opportunity, LLC now owns a much larger stake than it did earlier in the month, with the buying continuing across several trading days. While this does not guarantee near-term upside, it may help support investor sentiment if the market interprets the purchases as long-term conviction.
Negative Sentiment: Short interest in InMed Pharmaceuticals rose sharply in May, increasing to 134,109 shares as of May 29 from 26,599 shares two weeks earlier. A rising short position usually indicates that some traders expect more downside or remain unconvinced by the company’s fundamentals.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of InMed Pharmaceuticals in a report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

View Our Latest Stock Analysis on INM

InMed Pharmaceuticals Company Profile

(Get Free Report)

InMed Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Vancouver, British Columbia, that is dedicated to the discovery and development of novel therapeutics derived from cannabinoids. Leveraging a proprietary drug discovery engine, the company works to identify, design and optimize cannabinoid-based molecules with the goal of addressing diseases that have significant unmet medical needs. InMed’s integrated business model combines research, development and manufacturing capabilities under one roof to streamline the progression of promising assets from preclinical studies into human trials.

The company’s pipeline features multiple lead programs targeting both neurological and dermatological disorders.